• Ocular Therapeutix will hold investor one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on Sept. 10, 2026.
• A fireside chat is scheduled at the Baird 2026 Global Healthcare Conference on Sept. 15, 2026, 10:50-11:20 a.m. EDT.
• Phase 3 SOL-1 data on OTX-TKI in wet AMD will be presented at Retina Society on Sept. 24, 2026.
• The same SOL-1 results are slated for Euretina Congress on Oct. 2, 2026, 13:24-13:30 CEST.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010700PRIMZONEFULLFEED9818985) on September 01, 2026, and is solely responsible for the information contained therein.